TRVI logo

TRVI
Trevi Therapeutics Inc

1,791
Mkt Cap
$2.01B
Volume
178,630.00
52W High
$16.12
52W Low
$5.38
PE Ratio
-43.77
TRVI Fundamentals
Price
$14.22
Prev Close
$14.16
Open
$14.21
50D MA
$13.20
Beta
0.71
Avg. Volume
1.79M
EPS (Annual)
-$0.3173
P/B
10.56
Rev/Employee
$0.00
$1,499.53
Loading...
Loading...
News
all
press releases
HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)
HC Wainwright reaffirmed a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday...
News Placeholder
More News
News Placeholder
Trevi Therapeutics Q1 Earnings Call Highlights
Trevi Therapeutics (NASDAQ:TRVI) management used the company's first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering. Clinical program updates and upcoming trial starts Pres...
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07...
News Placeholder
Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday
Trevi Therapeutics (NASDAQ:TRVI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...
News Placeholder
Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI
Peregrine Capital Management LLC lowered its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 18.2% during the 4th quarter, according to its most recent disclosure with...
News Placeholder
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus recommendation of "Buy" by the twelve ratings firms that are currently covering the firm, Marketbeat.com reports...
News Placeholder
TRVI Stock’s Five-Day Rally Pushes It To An All-Time High – Here’s What’s Happening
The biotech firm priced its $150 million underwritten public offering at $13 per share, representing a roughly 10% discount from Thursday’s closing price.
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Still a Buy?
Trevi Therapeutics (NASDAQ:TRVI) Sees Large Volume Increase - Here's Why...
News Placeholder
D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)
D. Boral Capital reaffirmed a "buy" rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Friday...
News Placeholder
What's Going On With Trevi Therapeutics Stock?
Trevi Therapeutics shares are trading higher after it announced pricing of its $150 million offering of 11.6 million shares at $13 per share.read more...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available